4956-37-0Relevant articles and documents
Synthetic technology for oestradiol 17-heptanoate
-
Paragraph 0015-0020, (2019/04/04)
The invention discloses a synthetic technology for oestradiol 17-heptanoate, and further provides a preparation method for the oestradiol 17-heptanoate. The method comprises the following steps that 1, 17beta-estradiol serves as a raw material and reacts with heptanoyl chloride under the catalytic action of pyridine so as to obtain 3.17-diheptylic acid-17beta-estradiol; 2, the 3.17-diheptylic acid-17beta-estradiol in the step 1 serves as a raw material, in an alcohol solvent, hydrolysis reaction is carried out under the action of alkaline, and post-treatment is carried out so as to obtain a crude product of the oestradiol 17-heptanoate; and 3, the crude product of the oestradiol 17-heptanoate in the step 2 serves as a raw material, and refining is carried out by adopting methanol so as toobtain a refined product of the oestradiol 17-heptanoate. The preparation method for the oestradiol 17-heptanoate has the advantages that the technological method is simple, the yield of the target product is high, the production cost is low, the generation amount of chemical pollutants is small, and the method is suitable for industrial production.
Stability-indicating analysis of injectable estrogen-androgen combinations in formulations containing corn oil
Roman,Yates,Millar,O'Neill,Zweig
, p. 733 - 736 (2007/10/17)
A method was developed for the analysis of testosterone 17-enanthate 3-benzilic acid hydrazone, 17-β-estradiol 3,17-dienanthate, an estradiol benzoate combinations dissolved in an oily vehicle. Testosterone 17-enanthate 3-benzilic acid hydrazone was separated from the other drugs and vehicle components by chromatography on an acetonitrile-infusorial earth column followed by quantitation using UV spectroscopy. The estradiol esters were separated from the oil by an additional chromatographic step using a heptane-silanized infusorial earth column prior to quantitation by GLC. Subjecting formulations to elevated temperatures resulted in detectable losses for testosterone 17-enanthate 3-benzilic acid hydrazone and 17-β-estradiol 3,17-dienanthate. For both drugs, degradation was due to hydrolysis; the degradation products, testosterone 17-enanthate and 17-β-estradiol 17-enanthate, did not interfere with the intact drug determination. Methods also were developed to estimate degradation product levels in the formulation.